A Mixed-Method Study for Implementation of Central Line-Associated Bloodstream Infection Control in Intensive Care Units
Implementation of Central Line-Associated Bloodstream Infection Control in Intensive Care Unit Settings: A Mixed-Method Study
This is a phased mixed-method implementation study aiming to develop and evaluate a multi-component central-line-associated bloodstream infection (CLABSI) prevention bundle in three intensive-care units (Respiratory Intensive Care Unit, RICU; Surgical Intensive Care Unit, SICU; Neonatal Intensive Care Unit, NICU) at Peking University First Hospital. This study will first conduct pilot testing of the refined bundle in NICU, then scale-up implementation across all three ICUs. CLABSI incidence rate per 1000 central line-days is the primary outcome; bundle adherence rate and multi-dimensional implementation outcomes are secondary outcomes.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Shuo Li, M.D.
- Phone Number: +86-13671275323
- Email: shuoli_bjmu@126.com
Study Contact Backup
- Name: Xi Yao, MMSc
- Phone Number: +86-13811429675
- Email: yaoxi@pku.edu.cn
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100034
- Recruiting
- Peking University First Hospital
-
Contact:
- Shuo Li, M.D.
- Phone Number: +86-13671275323
- Email: shuoli_bjmu@126.com
-
Contact:
- Xi Yao, MMSc
- Phone Number: +86-13811429675
- Email: yaoxi@pku.edu.cn
-
Principal Investigator:
- Liuyi Li, MMSc
-
Principal Investigator:
- Hongling Chu, Ph.D.
-
Principal Investigator:
- Xi Yao, MMSc
-
Sub-Investigator:
- Meihua Hu, MMSc
-
Sub-Investigator:
- Yuan Cheng, M.D.
-
Sub-Investigator:
- Tian Sang, M.D.
-
Sub-Investigator:
- Cui Yuan, MMSc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Admitted to RICU, SICU or NICU of Peking University First Hospital during study period
- Has an indwelling central venous catheter (CVC, non-tunneled), peripherally inserted central catheter (PICC), or umbilical venous catheter (UVC)
- Generates central-line-days within study observation window
Exclusion Criteria:
- CVC placed in external hospitals and not managed within the three participating ICUs
- Central-line-days generated outside study observation period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CLABSI Prevention Bundle Intervention Arm
Single-group intervention, implementing multi-component CLABSI prevention bundle in NICU, RICU and SICU with phased roll-out |
A multi-component CLABSI prevention bundle with six core measures: (1) preferable insertion site selection, (2) hand hygiene, (3) maximum sterile barrier precautions, (4) catheter hub disinfection and insertion site care, (5) timely removal of non-essential catheters, and (6) implementation of a standardized checklist. The study adopts a phased implementation design: a pilot phase will first be conducted in NICU to test the bundle, identify implementation barriers, and refine local strategies; after optimization, the refined bundle will be rolled out across RICU, SICU and NICU. Local implementation teams will develop tailored action plans, monitor adherence, and iteratively optimize implementation strategies throughout the study. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CLABSI incidence rate
Time Frame: Baseline through intervention period, up to 36 months
|
CLABSI cases per 1000 central-line-days, defined according to Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) criteria. Calculated as number of CLABSI events divided by total central-line-days multiplied by 1000, collected prospectively in RICU, SICU and NICU. |
Baseline through intervention period, up to 36 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall CLABSI prevention bundle adherence score
Time Frame: Baseline through implementation period, up to 36 months
|
A composite adherence score calculated as the mean proportion of correctly performed elements across six core CLABSI-prevention bundle measures (hand hygiene, maximum sterile barrier precautions, preferable insertion site, disinfection and site care, nonessential catheter removal, and checklist completion), assessed by direct observation and chart review. The score is expressed as a single percentage ranging from 0% to 100%. |
Baseline through implementation period, up to 36 months
|
|
Acceptability of the CLABSI prevention intervention bundle
Time Frame: Entire study duration, up to 36 months
|
Acceptability will be assessed through semi-structured interviews with healthcare professionals involved in implementation to explore perceptions of whether the intervention bundle is agreeable and satisfactory in routine clinical practice. Findings will be reported as qualitative themes and categories. |
Entire study duration, up to 36 months
|
|
Fidelity of implementation of the intervention bundle - Quantitative assessment
Time Frame: Entire study duration, up to 36 months
|
The degree to which the intervention bundle is implemented as intended according to predefined implementation procedures, assessed by quantitative process indicators, case audits, and checklists. Fidelity will be reported as the proportion of predefined procedures correctly completed. |
Entire study duration, up to 36 months
|
|
Fidelity of implementation of the intervention bundle - Qualitative assessment
Time Frame: Entire study duration, up to 36 months
|
The degree to which the intervention bundle is implemented as intended, assessed through semi-structured interviews with implementation stakeholders. Qualitative findings regarding barriers and facilitators to implementation fidelity will be reported as themes. |
Entire study duration, up to 36 months
|
|
Feasibility of implementation of the intervention bundle
Time Frame: Entire study duration, up to 36 months
|
Feasibility will be assessed through semi-structured interviews with healthcare professionals to determine the extent to which the intervention bundle can be successfully implemented within participating intensive care units. Findings will be reported as qualitative themes describing barriers and facilitators to implementation. |
Entire study duration, up to 36 months
|
|
Sustainability of implementation of the intervention bundle - Quantitative assessment
Time Frame: Entire study duration, up to 36 months
|
The extent to which implementation of the intervention bundle is maintained over time, assessed using quantitative process indicators. Sustainability will be reported as the proportion of bundle elements continued in routine clinical practice. |
Entire study duration, up to 36 months
|
|
Sustainability of implementation of the intervention bundle - Qualitative assessment
Time Frame: Entire study duration, up to 36 months
|
The extent to which implementation of the intervention bundle is integrated into routine clinical practice over time, assessed through semi-structured interviews. Qualitative findings will be reported as themes. |
Entire study duration, up to 36 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Shuo Li, M.D., Peking University First Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2024-197-002
- 23-515 (Other Grant/Funding Number: China Medical Board)
- 2024研197-002 (Other Identifier: Peking University First Hospital Ethics Committee)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual-participant data will not be shared publicly because of patient privacy restrictions and local institutional data security requirements. Aggregated study results may be published in peer-reviewed journals.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.